Ratings on Two Delta-Related Synthetic Deals Affirmed, Removed From CreditWatch Negative Jul 03

  • ID: 1929094
  • July 2003
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) July 9, 2003--Standard & Poor's Ratings Services today affirmed its ratings on the class A-1 certificates issued by Corporate Backed Trust Certificates Series 2001-6 Trust and Corporate Backed Trust Certificates Series 2001-19 Trust. At the same time, the ratings are removed from CreditWatch with negative implications, where they were placed March 20, 2003 (see list). The series 2001-6 and 2001-19 Corporate Backed Trust Certificates Trusts are synthetic transactions that are weak-linked to the underlying securities, Delta Air Lines Inc.'s 8.3% senior unsecured notes due Dec. 15, 2029. The rating actions reflect the affirmed ratings on Delta Air Lines and their removal from CreditWatch July 8, 2003. A copy of the Delta Air Lines Inc.-related press...

Companies mentioned in this report are:
- Delta Air Lines Inc.

Action: Affirmed, Off CreditWatch

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Delta Air Lines Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.